Skip to main content
ABCLAbCellera Biologics Inc.Sell5.2·$11.98

AbCellera Biologics (ABCL) Q3 2026 earnings — TrendMatrix coverage

BEAT · SMALLER LOSS+24.9% vs estimateEPS -$0.13 vs -$0.17 estCurrent verdict Sell 5.2/10

Reported

Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure · Editorial policy

Event detail · Q3 2026

Key numbers

Adjusted EPS
-$0.13
Estimate
-$0.17
Surprise
+24.9%
Revenue (period 2026-09-30)
$10.6M
Score today
5.2/10

Revenue source: xbrl.

Report record · Q3 2026

How the report landed

AbCellera Biologics (ABCL) reported a narrower loss than forecast — adjusted EPS of -$0.13 against the -$0.17 estimate (a 24.9% beat on a still-unprofitable quarter).

Around the report

Coverage in the report window

  • Stifel Raises Price Target for AbCellera Biologics — fiscal.ai, 2026-11-10
  • Stifel Maintains Buy on AbCellera Biologics, Raises Price Target to $14 — benzinga, 2026-11-10
  • AbCellera Reports Q3 2026 Business Results — fiscal.ai, 2026-11-09
Current read · as of 2026-11-10

Where TrendMatrix's rating stands now

TrendMatrix currently rates ABCL Sell at 5.2/10; no pre/post engine snapshot brackets this report.

3 of the last 4 quarters beat the estimate; this quarter's +24.9% surprise compares with a +32.1% four-quarter average.

What argues against it

  • Quality below floor (2.1 < 4.0)
  • Value-trap signals (3/5): Revenue declining (-90.6% YoY), Margin compression (op margin -567.2%), Negative free cash flow
  • Momentum score 2.7/10 — below 4.5 minimum

This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.

Current engine read

The levels TrendMatrix's engine tracks

Current price
$11.98
Price target
$14.94
Stop
$11.14
Upside to target
+24.7%
Reward-to-risk
1.6:1

Model outputs from TrendMatrix’s engine as of 2026-11-10 — shown for context, not personalized investment advice.

Healthcare context

ABCL at TrendMatrix's latest read

Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.

Industry
Biotechnology
Market cap
$4.05B
P/E (fwd)
-16.7
52-week range
$2.75–$15.02
Off 52-week high
20.2%
RSI (14)
49
Volume vs avg
0.47×
Score today
5.2/10

EPS and the estimate come from Yahoo Finance’s earnings calendar, captured around the report date. That EPS is the adjusted figure analysts forecast, so it can differ from the GAAP diluted EPS in the company’s filing, and consensus estimates vary between data providers. Revenue comes from SEC XBRL company facts where available, yfinance-provisional otherwise. Not a buy/sell rating, a price target, or investment advice — see the current verdict on the stock’s main page for TrendMatrix’s live read.

Home › Stocks › ABCL › Earnings › Q3 2026 earnings